GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citi Pharma Ltd (KAR:CPHL) » Definitions » EBITDA Margin %

Citi Pharma (KAR:CPHL) EBITDA Margin % : 0.00% (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is Citi Pharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Citi Pharma's EBITDA for the six months ended in . 20 was ₨0.00 Mil. Citi Pharma's Revenue for the six months ended in . 20 was ₨0.00 Mil. Therefore, Citi Pharma's EBITDA margin for the quarter that ended in . 20 was 0.00%.


Citi Pharma EBITDA Margin % Historical Data

The historical data trend for Citi Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citi Pharma EBITDA Margin % Chart

Citi Pharma Annual Data
Trend
EBITDA Margin %

Citi Pharma Semi-Annual Data
EBITDA Margin %

Competitive Comparison of Citi Pharma's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Citi Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Citi Pharma's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citi Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Citi Pharma's EBITDA Margin % falls into.


;
;

Citi Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Citi Pharma's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

Citi Pharma's EBITDA Margin % for the quarter that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Citi Pharma  (KAR:CPHL) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Citi Pharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Citi Pharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Citi Pharma Business Description

Traded in Other Exchanges
N/A
Address
588 Q Block, Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its departments include Active Pharma Ingredients (API) and Formulations. Some of its products include Askprol C Tab, Lenon Tab, Recoz Tab, Cingol Tab among others.

Citi Pharma Headlines

No Headlines